Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1990 Apr;80(1):44–48. doi: 10.1111/j.1365-2249.1990.tb06439.x

Increased serum neopterin in patients with HIV-1 infection is correlated with reduced in vitro interleukin-2 production.

D Fuchs 1, G M Shearer 1, R N Boswell 1, M Clerici 1, G Reibnegger 1, E R Werner 1, R A Zajac 1, H Wachter 1
PMCID: PMC1535232  PMID: 1969780

Abstract

Recently we have observed that the CD4+ T cell response of peripheral blood mononuclear cells (PBMC) to soluble antigens is the first to be lost in the course of HIV-1 infection followed by the loss of response to HLA alloantigens. In this study we compared serum neopterin concentrations of individuals with early stages of HIV-1 infection (stages WR1 and WR2, Walter Reed staging system) with in vitro interleukin-2 (IL-2) production of PBMC in response to stimulation with soluble antigens (influenza A virus and tetanus toxoid) and alloantigens. Neopterin concentrations were significantly higher in HIV-1-seropositive individuals who showed deficient IL-2 production in response to recall antigens only or to all of the stimuli tested in vitro, compared with HIV-1-seropositive individuals who exhibited no CD4+ T cell defects. No difference in serum neopterin concentrations was observed between the group that was functionally deficient to soluble antigens only versus those who were unresponsive to both types of stimuli. It appears that the selective loss of the MHC self-restricted CD4+ T cell function is associated with an increase in serum neopterin levels. Neopterin concentrations are an estimate of the activation status of macrophages. We conclude that defective in vitro production of lymphokines by T lymphocytes is associated with activated macrophages in vivo.

Full text

PDF
47

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ascher M. S., Sheppard H. W. AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol. 1988 Aug;73(2):165–167. [PMC free article] [PubMed] [Google Scholar]
  2. Biddison W. E., Sharrow S. O., Shearer G. M. T cell subpopulations required for the human cytotoxic T lymphocyte response to influenza virus: evidence for T cell help. J Immunol. 1981 Aug;127(2):487–491. [PubMed] [Google Scholar]
  3. Clerici M., Stocks N. I., Zajac R. A., Boswell R. N., Bernstein D. C., Mann D. L., Shearer G. M., Berzofsky J. A. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature. 1989 Jun 1;339(6223):383–385. doi: 10.1038/339383a0. [DOI] [PubMed] [Google Scholar]
  4. Cleveland M. G., Annable C. R., Klimpel G. R. In vivo and in vitro production of IFN-beta and IFN-gamma during graft vs host disease. J Immunol. 1988 Nov 15;141(10):3349–3356. [PubMed] [Google Scholar]
  5. Daniel V., Schimpf K., Opelz G. Lymphocyte autoantibodies and alloantibodies in HIV-positive haemophilia patients. Clin Exp Immunol. 1989 Feb;75(2):178–183. [PMC free article] [PubMed] [Google Scholar]
  6. Fauci A. S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988 Feb 5;239(4840):617–622. doi: 10.1126/science.3277274. [DOI] [PubMed] [Google Scholar]
  7. Fuchs D., Hausen A., Hengster P., Reibnegger G., Schulz T., Werner E. R., Dierich M. P., Wachter H. In vivo activation of CD4+ cells in AIDS. Science. 1987 Jan 16;235(4786):356–356. doi: 10.1126/science.3099388. [DOI] [PubMed] [Google Scholar]
  8. Fuchs D., Hausen A., Reibnegger G., Werner E. R., Dierich M. P., Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today. 1988 May;9(5):150–155. doi: 10.1016/0167-5699(88)91203-0. [DOI] [PubMed] [Google Scholar]
  9. Fuchs D., Malkovsky M., Reibnegger G., Werner E. R., Forni G., Wachter H. Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett. 1989 Dec;23(2):103–108. doi: 10.1016/0165-2478(89)90120-x. [DOI] [PubMed] [Google Scholar]
  10. Fuchs D., Reibnegger G., Wachter H., Jaeger H., Popescu M., Kaboth W. Neopterin levels correlating with the Walter Reed staging classification in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1987 Nov;107(5):784–785. doi: 10.7326/0003-4819-107-5-784_2. [DOI] [PubMed] [Google Scholar]
  11. Fuchs D., Spira T. J., Hausen A., Reibnegger G., Werner E. R., Felmayer G. W., Wachter H. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem. 1989 Aug;35(8):1746–1749. [PubMed] [Google Scholar]
  12. Gowda S. D., Stein B. S., Mohagheghpour N., Benike C. J., Engleman E. G. Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. J Immunol. 1989 Feb 1;142(3):773–780. [PubMed] [Google Scholar]
  13. Huang Y. P., Miescher P. A., Zubler R. H. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol. 1986 Dec 1;137(11):3515–3520. [PubMed] [Google Scholar]
  14. Huber C., Batchelor J. R., Fuchs D., Hausen A., Lang A., Niederwieser D., Reibnegger G., Swetly P., Troppmair J., Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984 Jul 1;160(1):310–316. doi: 10.1084/jem.160.1.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kloster B. E., John P. A., Miller L. E., Rubin L. A., Nelson D. L., Blair D. C., Tomar R. H. Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol. 1987 Dec;45(3):440–446. doi: 10.1016/0090-1229(87)90095-x. [DOI] [PubMed] [Google Scholar]
  16. Lähdevirta J., Maury C. P., Teppo A. M., Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Sep;85(3):289–291. doi: 10.1016/0002-9343(88)90576-1. [DOI] [PubMed] [Google Scholar]
  17. Macatonia S. E., Patterson S., Knight S. C. Suppression of immune responses by dendritic cells infected with HIV. Immunology. 1989 Jul;67(3):285–289. [PMC free article] [PubMed] [Google Scholar]
  18. McDougal J. S., Mawle A., Cort S. P., Nicholson J. K., Cross G. D., Scheppler-Campbell J. A., Hicks D., Sligh J. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol. 1985 Nov;135(5):3151–3162. [PubMed] [Google Scholar]
  19. Murray H. W., Hillman J. K., Rubin B. Y., Kelly C. D., Jacobs J. L., Tyler L. W., Donelly D. M., Carriero S. M., Godbold J. H., Roberts R. B. Patients at risk for AIDS-related opportunistic infections. Clinical manifestations and impaired gamma interferon production. N Engl J Med. 1985 Dec 12;313(24):1504–1510. doi: 10.1056/NEJM198512123132403. [DOI] [PubMed] [Google Scholar]
  20. Preble O. T., Rothko K., Klippel J. H., Friedman R. M., Johnston M. I. Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med. 1983 Jun 1;157(6):2140–2146. doi: 10.1084/jem.157.6.2140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Prince H. E., John J. K. Abnormalities of interleukin 2 receptor expression associated with decreased antigen-induced lymphocyte proliferation in patients with AIDS and related disorders. Clin Exp Immunol. 1987 Jan;67(1):59–65. [PMC free article] [PubMed] [Google Scholar]
  22. Redfield R. R., Wright D. C., Tramont E. C. The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med. 1986 Jan 9;314(2):131–132. doi: 10.1056/NEJM198601093140232. [DOI] [PubMed] [Google Scholar]
  23. Troppmair J., Nachbaur K., Herold M., Aulitzky W., Tilg H., Gastl G., Bieling P., Kotlan B., Flener R., Mull B. In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS). Clin Exp Immunol. 1988 Dec;74(3):392–397. [PMC free article] [PubMed] [Google Scholar]
  24. Wachter H., Fuchs D., Hausen A., Huber C., Knosp O., Reibnegger G., Spira T. J. Elevated urinary neopterin levels in patients with the acquired immunodeficiency syndrome (AIDS). A preliminary report. Hoppe Seylers Z Physiol Chem. 1983 Sep;364(9):1345–1346. doi: 10.1515/bchm2.1983.364.2.1345. [DOI] [PubMed] [Google Scholar]
  25. Wachter H., Fuchs D., Hausen A., Reibnegger G., Werner E. R. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem. 1989;27:81–141. doi: 10.1016/s0065-2423(08)60182-1. [DOI] [PubMed] [Google Scholar]
  26. Werner-Felmayer G., Werner E. R., Fuchs D., Hausen A., Reibnegger G., Wachter H. Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler. 1989 Sep;370(9):1063–1069. doi: 10.1515/bchm3.1989.370.2.1063. [DOI] [PubMed] [Google Scholar]
  27. Werner E. R., Bichler A., Daxenbichler G., Fuchs D., Fuith L. C., Hausen A., Hetzel H., Reibnegger G., Wachter H. Determination of neopterin in serum and urine. Clin Chem. 1987 Jan;33(1):62–66. [PubMed] [Google Scholar]
  28. Wright S. C., Jewett A., Mitsuyasu R., Bonavida B. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol. 1988 Jul 1;141(1):99–104. [PubMed] [Google Scholar]
  29. de la Barrera S., Fainboim L., Lugo S., Picchio G. R., Muchinik G. R., de Bracco M. M. Anti-class II antibodies in AIDS patients and AIDS-risk groups. Immunology. 1987 Dec;62(4):599–604. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES